BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 15607936)

  • 21. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
    Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
    Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women.
    Smith TJ; Hillner BE
    J Clin Oncol; 1993 Apr; 11(4):771-6. PubMed ID: 8478670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemoprevention: drug pricing and mortality: the case of tamoxifen.
    Melnikow J; Kuenneth C; Helms LJ; Barnato A; Kuppermann M; Birch S; Nuovo J
    Cancer; 2006 Sep; 107(5):950-8. PubMed ID: 16865680
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer.
    Hornberger J; Cosler LE; Lyman GH
    Am J Manag Care; 2005 May; 11(5):313-24. PubMed ID: 15898220
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States.
    Lyman GH; Lalla A; Barron RL; Dubois RW
    Clin Ther; 2009 May; 31(5):1092-104. PubMed ID: 19539110
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A model of chemotherapy in node-negative breast cancer.
    Hillner BE; Smith TJ
    J Natl Cancer Inst Monogr; 1992; (11):143-9. PubMed ID: 1627420
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy.
    Navari RM; Brenner MC; Wilson MN
    Breast Cancer Res Treat; 2008 Nov; 112(1):197-201. PubMed ID: 18064563
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of the 21-gene assay for guiding adjuvant chemotherapy decisions in early breast cancer.
    Paulden M; Franek J; Pham B; Bedard PL; Trudeau M; Krahn M
    Value Health; 2013; 16(5):729-39. PubMed ID: 23947965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
    ; Colleoni M; Gelber S; Goldhirsch A; Aebi S; Castiglione-Gertsch M; Price KN; Coates AS; Gelber RD
    J Clin Oncol; 2006 Mar; 24(9):1332-41. PubMed ID: 16505417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer.
    Owusu C; Buist DS; Field TS; Lash TL; Thwin SS; Geiger AM; Quinn VP; Frost F; Prout M; Yood MU; Wei F; Silliman RA
    J Clin Oncol; 2008 Feb; 26(4):549-55. PubMed ID: 18071188
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant endocrine therapy for early breast cancer.
    Andreetta C; Smith I
    Cancer Lett; 2007 Jun; 251(1):17-27. PubMed ID: 17150303
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Which patients with estrogen receptor-positive early breast cancer should be treated with adjuvant chemotherapy?
    Chiuri VE; Lorusso V
    Oncology; 2009; 77 Suppl 1():18-22. PubMed ID: 20130428
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reliable data on 5- and 10-year survival provide accurate estimates of 15-year survival in estrogen receptor-positive early-stage breast cancer.
    Herold CI; Djulbegovic B; Hozo I; Lyman GH
    Breast Cancer Res Treat; 2010 Jun; 121(3):771-6. PubMed ID: 19806449
    [TBL] [Abstract][Full Text] [Related]  

  • 35. When to recommend and to pay for first-line adjuvant breast cancer treatment? A structured review of the literature.
    Kilian R; Porzsolt F
    Breast; 2005 Dec; 14(6):636-42. PubMed ID: 16183288
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
    Regan MM; Viale G; Mastropasqua MG; Maiorano E; Golouh R; Carbone A; Brown B; Suurküla M; Langman G; Mazzucchelli L; Braye S; Grigolato P; Gelber RD; Castiglione-Gertsch M; Price KN; Coates AS; Goldhirsch A; Gusterson B;
    J Natl Cancer Inst; 2006 Nov; 98(21):1571-81. PubMed ID: 17077359
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort.
    Elkin EB; Hurria A; Mitra N; Schrag D; Panageas KS
    J Clin Oncol; 2006 Jun; 24(18):2757-64. PubMed ID: 16782916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of ovarian ablation in the management of breast cancer.
    Wirk B
    Breast J; 2005; 11(6):416-24. PubMed ID: 16297086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progesterone receptor status provides predictive value for adjuvant endocrine therapy in older estrogen receptor-positive breast cancer patients.
    Yu KD; Liu GY; Di GH; Wu J; Lu JS; Shen KW; Shen ZZ; Shao ZM
    Breast; 2007 Jun; 16(3):307-15. PubMed ID: 17293115
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93.
    ; Rudenstam CM; Zahrieh D; Forbes JF; Crivellari D; Holmberg SB; Rey P; Dent D; Campbell I; Bernhard J; Price KN; Castiglione-Gertsch M; Goldhirsch A; Gelber RD; Coates AS
    J Clin Oncol; 2006 Jan; 24(3):337-44. PubMed ID: 16344321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.